At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 23 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study
In Brief
A Phase 4 clinical trial evaluating Liraglutide and Placebo for Type 2 Diabetes. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesFinland
CollaboratorsGöteborg University
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartFeb 2015
First PostedMay 2016
Primary CompletionFeb 2019
TodayJul 2026
First PostedMay 6, 2016
Enrollment StartFeb 1, 2015
Primary CompletionFeb 28, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 10.2 years ago
Interventions
Liraglutidedrug
Placebodrug